Transarterial hepatic yttrium-90 radioembolization for treatment of unresectable intrahepatic cholangiocarcinoma

Record ID 32013000288
English
Authors' recomendations: Cholangiocarcinomas are malignancies of the biliary tract that can be either intrahepatic or extrahepatic. These cancers are rare and account for fewer than 3% of the malignancies in the United States. The 5-year survival rate is approximately 30% to 40% for intrahepatic cancers after resection with curative intent. However, cholangiocarcinomas are typically diagnosed at an advanced stage of disease and only 10% of the cases are eligible for curative resection. For patients receiving palliative care, the median survival duration is fewer than 6 months. Chemotherapy alone has minimal effects on local tumor control and on survival, and is more efficacious when combined with radiotherapy, or when used as a neoadjuvant to reduce tumor size and allow surgical resection. External radiotherapy can have a palliative effect; however, it carries the risk of radiation toxicity to healthy liver tissue.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Angiography
  • Yttrium Radioisotopes
  • Liver Neoplasms
  • Embolization, Therapeutic
  • Cholangiocarcinoma
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.